Recent Posts in ‘Biotech News’
AtheroNova (AHRO) Mentioned by Analyst in Life Sciences Report
Mont Blanc Capital Equity Research issued a research update on May 14, 2013 for AtheroNova Inc. (OTC Markets: AHRO). In the report, the analyst maintained its Buy rating and $2.00 per share price target, while projecting that Phase I clinical trials would begin next month after the company received approval from the Russian Ministry of
Investors Begin To Realize RNA’s Potential
Cancer, cardiovascular diseases and autoimmune diseases are among the most exciting fields in the pharmaceutical industry. While large and small molecule drugs have addressed targeted needs, the market is fragmented and lacks a unified platform that is able to broadly treat all areas. But, recent breakthroughs in RNA-based therapeutics could provide the answer. Selectively Targeting
The Ohio State University Begins Animal Study to Support Vycor’s (VYCO) VBAS Technology
Vycor Medical Inc. (OTCQB: VYCO), a medical device company with a suite of FDA approved products, recently announced that Ohio State University has commenced an animal study which the Company hopes will support its ViewSite™ Brain Access System (“VBAS”) as a less invasive neurosurgical device for brain access than the standard of care “ blade
RXi Pharma (RXII) to Expand Investor Awareness to Jeffries Healthcare Conference
RXi Pharmaceuticals Corporation (OTC Markets: RXII), a biotechnology company focused on innovative therapies addressing major unmet medical needs using RNA-targeted technologies, recently announced that CEO Dr. Geert Cauwenbergh would discuss the development of RXI-109 at the Jeffries Healthcare Conference on June 6th, 2013 at 10:00am EDT. With over 300 presenting companies and 2,000 attendees last
Arrayit (ARYC) Turns a Page with First Quarter Profit
Arrayit Corp. (OTC Markets: ARYC) reported revenues that jumped 66% to $942,916 during the first quarter, with net income that swung from a loss of $1,344,651 to a profit of $235,478 year over year. With rising revenues and sustainable operations, the company’s management team has successfully executed on its promises to unlock long-term value for
Finding the Next Big Blockbuster Drug
The pharmaceutical industry is largely centered on blockbuster drugs, with the top 20 drugs in the U.S. accounting for nearly $320 billion in sales in 2011. With five of those 20 drugs losing patent protection since then, there has been a high premium placed on finding the next big blockbuster drug on the part of
RXi Pharma (RXII) Reports Steady Progress in Q1 2013
RXi Pharmaceuticals Corporation (OTCQB: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, reported significant progress during the first quarter as it nears the end of its Phase I clinical development stage for RXI-109. With a fresh capital infusion and solid clinical progress, investors
AtheroNova Receives Russia’s Approval for Phase I Clinical Trials
AtheroNova Inc. (OTCQB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, has spent the last few months building up its scientific team ahead of clinical trials. And with Russia’s approval secured, the company is now ready to begin proving
RXi Pharma (RXII) to Showcase RXI-109 at Key Conference
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major medical needs using RNA-targeted technologies, has been building awareness in both the scientific and investment communities at a number of conferences so far this year. In addition to the presenting its technology at the IBC’s 15th Annual
Cardium’s (CXM) Generx Published in April Issue of Molecular Therapy
Cardium Therapeutics (NYSE MKT: CXM), a health sciences and regenerative medicine company focused on unlocking the value in medical assets, has pioneered a new gene therapy targeting heart disease that takes a different approach than stent-makers like Medtronic Inc. (NYSE: MDT) or molecular therapy companies like Amgen Inc. (NASDAQ: AMGN). Generx is a DNA-based angiogenic
Cardium (CXM) Expands Awareness of Excellagen® at Industry Conference
Cardium Therapeutics Ltd. (NYSE MKT: CXM), an asset-based health sciences and regenerative medicine company focused on unlocking the value in innovative medical assets, continues to expand awareness of the clinical benefits of its Excellagen® product for wound care. The FDA-cleared, syringe-based collagen gel targets patients in the same industry as companies like Synovis Life Technologies
RXi Pharmaceuticals to Present Monday, May 6th at ARVO Annual Meeting
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announces that they will be presenting an overview of the use of sd-rxRNAs® in the eye and highlighting specifically RXi’s work in the areas of retinoblastoma and proliferative vitreoretinopathy.